316 related articles for article (PubMed ID: 34846533)
21. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.
Chung H; He S; Nasreen S; Sundaram ME; Buchan SA; Wilson SE; Chen B; Calzavara A; Fell DB; Austin PC; Wilson K; Schwartz KL; Brown KA; Gubbay JB; Basta NE; Mahmud SM; Righolt CH; Svenson LW; MacDonald SE; Janjua NZ; Tadrous M; Kwong JC;
BMJ; 2021 Aug; 374():n1943. PubMed ID: 34417165
[TBL] [Abstract][Full Text] [Related]
23. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.
Hall V; Foulkes S; Insalata F; Kirwan P; Saei A; Atti A; Wellington E; Khawam J; Munro K; Cole M; Tranquillini C; Taylor-Kerr A; Hettiarachchi N; Calbraith D; Sajedi N; Milligan I; Themistocleous Y; Corrigan D; Cromey L; Price L; Stewart S; de Lacy E; Norman C; Linley E; Otter AD; Semper A; Hewson J; D'Arcangelo S; Chand M; Brown CS; Brooks T; Islam J; Charlett A; Hopkins S;
N Engl J Med; 2022 Mar; 386(13):1207-1220. PubMed ID: 35172051
[TBL] [Abstract][Full Text] [Related]
24. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
Wei Y; Jia KM; Zhao S; Hung CT; Mok CKP; Poon PKM; Man Leung EY; Wang MH; Yam CHK; Chow TY; Guo Z; Yeoh EK; Chong KC
JAMA Netw Open; 2023 Feb; 6(2):e2254777. PubMed ID: 36735253
[TBL] [Abstract][Full Text] [Related]
25. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses.
Andersson NW; Thiesson EM; Baum U; Pihlström N; Starrfelt J; Faksová K; Poukka E; Lund LC; Hansen CH; Aakjær M; Kjær J; Cohet C; Goossens M; Andersen M; Hallas J; Meijerink H; Ljung R; Hviid A
BMJ; 2023 Jul; 382():e074325. PubMed ID: 37487623
[TBL] [Abstract][Full Text] [Related]
27. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
[TBL] [Abstract][Full Text] [Related]
28. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
[TBL] [Abstract][Full Text] [Related]
29. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.
Florentino PTV; Millington T; Cerqueira-Silva T; Robertson C; de Araújo Oliveira V; Júnior JBS; Alves FJO; Penna GO; Vital Katikireddi S; Boaventura VS; Werneck GL; Pearce N; McCowan C; Sullivan C; Agrawal U; Grange Z; Ritchie LD; Simpson CR; Sheikh A; Barreto ML; Rudan I; Barral-Netto M; Paixão ES
Lancet Infect Dis; 2022 Nov; 22(11):1577-1586. PubMed ID: 35952702
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
Barda N; Dagan N; Cohen C; Hernán MA; Lipsitch M; Kohane IS; Reis BY; Balicer RD
Lancet; 2021 Dec; 398(10316):2093-2100. PubMed ID: 34756184
[TBL] [Abstract][Full Text] [Related]
32. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
[TBL] [Abstract][Full Text] [Related]
33. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
[TBL] [Abstract][Full Text] [Related]
34. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Magen O; Waxman JG; Makov-Assif M; Vered R; Dicker D; Hernán MA; Lipsitch M; Reis BY; Balicer RD; Dagan N
N Engl J Med; 2022 Apr; 386(17):1603-1614. PubMed ID: 35417631
[TBL] [Abstract][Full Text] [Related]
35. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
Monge S; Rojas-Benedicto A; Olmedo C; Mazagatos C; José Sierra M; Limia A; Martín-Merino E; Larrauri A; Hernán MA;
Lancet Infect Dis; 2022 Sep; 22(9):1313-1320. PubMed ID: 35658998
[TBL] [Abstract][Full Text] [Related]
37. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
[TBL] [Abstract][Full Text] [Related]
38. Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel.
Prunas O; Weinberger DM; Pitzer VE; Gazit S; Patalon T
Clin Infect Dis; 2023 Jan; 76(1):113-118. PubMed ID: 36484301
[TBL] [Abstract][Full Text] [Related]
39. Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents.
Oliveira CR; Niccolai LM; Sheikha H; Elmansy L; Kalinich CC; Grubaugh ND; Shapiro ED;
JAMA Netw Open; 2022 Mar; 5(3):e220935. PubMed ID: 35238933
[TBL] [Abstract][Full Text] [Related]
40. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
Gazit S; Shlezinger R; Perez G; Lotan R; Peretz A; Ben-Tov A; Herzel E; Alapi H; Cohen D; Muhsen K; Chodick G; Patalon T
Ann Intern Med; 2022 May; 175(5):674-681. PubMed ID: 35157493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
